With obesity, muscle loss, and sleep disorders so prominent in postmenopause, providers are now looking into further expansion of GLP-1 use.
|Articles|November 28, 2012
DEA serves notice to three Florida pharmacies
The Drug Enforcement Administration (DEA) issued a notice to three Walgreens pharmacies in Florida on Nov. 27, asking them to show why the DEA should not revoke their DEA registrations.
Advertisement
Advertisement
Related to this article
Menopause status and symptoms are inconsistently captured in electronic health records, leaving a gap in care for patients.
As midterm elections approach, the pharmacy industry is backing one of its most meaningful bills yet while the current congressional session wanes.
Data found reduced cardiovascular risk with hormone therapy, particularly among Black women and those starting treatment within 10 years of menopause.
Eli Lilly’s new indication helps improve medication delivery for adults with type 2 diabetes, reducing annual injections by over 300.
Pennsylvania has become the center of the outbreak as cases exceed 775 alongside conflicting mortality reports.
The LATA trial found long-acting cabotegravir–rilpivirine is better than daily oral therapy at keeping adolescents virologically suppressed.
The update adds efficacy and safety data on adults newly diagnosed with pulmonary arterial hypertension.
Advertisement
Advertisement
Trending on Drug Topics
1
Injectable HIV Treatment Beats Daily Pills in Adolescent Trial
2
Study Finds Reduced Cardiovascular Risk With Hormone Therapy Initiation
3
FDA Approves Onswik Weekly Insulin for Adults With T2D
4
Muscle Preservation Is Key in GLP-1 Therapy for Postmenopausal Women
5